Reviews/TNF Alpha Inhibitors/TNF-alpha inhibitors are effective in psoriatic arthritis
· TN-SPA-02 · v2
This corpus asks whether anti-TNF drugs help people with psoriatic arthritis, a joint disease linked to psoriasis. A randomised adalimumab trial and its extension reported that 56%, 44% and 30% of patients reached increasing levels of joint improvement [7], and a large phase-3 trial found 65.0% of adalimumab patients improved versus 36.2% on placebo [8]. A further trial simply treats anti-TNF efficacy as settled background [3], and very large real-world registries show swelling clearing in the joints [9] and patients reaching remission [11] while on these drugs. Nothing in the corpus points the other way. The panel landed where it did because randomised and real-world evidence agree on the direction of benefit, with the open questions being about how large the effect is rather than whether it exists.
The corpus contains randomised evidence for adalimumab specifically: ACR20/50/70 response of 56%, 44% and 30% at 48 weeks [7], and a phase-3 trial where adalimumab reached ACR20 of 65.0% against 36.2% on placebo [8]. A tapering trial states outright that TNF inhibitors are effective in psoriatic arthritis [3]. Large observational datasets corroborate this: a nine-registry cohort of 1729 patients tracked resolution of joint swelling on a first TNFi [9], a 15,332-patient registry reported remission with a comedication odds ratio of 1.25 [11], and a real-world cohort showed DAPSA improvement on adalimumab [1]. A target-trial emulation found TNFi comparably effective to IL-17 and IL-23 inhibitors [10]. The contested point: The division is not over whether TNF inhibitors work but over how directly the corpus proves it: the most adalimumab-specific result [7] is open-label extension rather than a maintained placebo contrast, and the cleanest placebo-referenced figure [8] comes from a trial whose actual subject is upadacitinib, with adalimumab only as an active comparator. The remaining support leans heavily on observational registries [1][9][10][11] carrying confounding by indication.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from TNF Alpha Inhibitors, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The most direct adalimumab evidence [7] is 48-week open-label extension data, not a maintained placebo comparison; the controlled placebo contrast at that timepoint is absent from the corpus.
The cleanest placebo-referenced TNFi result [8] comes from a conference abstract in which adalimumab is the active comparator rather than the trial's investigational subject.
Where it remains uncertain. The strongest adalimumab-specific data are open-label extension [7] and the cleanest placebo contrast is from a trial in which adalimumab is only the comparator [8], leaving direct placebo-controlled TNFi trials thinner than the claim's breadth implies.
Aleatory
Resolution of swelling on TNFi differed by anatomical site in a 1729-patient cohort [9], so individual joint response is intrinsically variable.
Epistemic
The adalimumab-specific efficacy figures [7] are open-label extension; the corpus lacks a sustained placebo comparison at that timepoint for the TNFi subject itself.
Inferential
Remission [11], DAPSA improvement [1], swelling resolution [9] and comparative effectiveness [10] are observational, so benefit may be inflated by who receives TNFi.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
RCT states TNFi effectiveness in PsA; tapering cohort maintained low disease activity.
“Tumour necrosis factor inhibitors (TNFi) are effective in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA)”
Panel auditInternal validity: medium · scope of inference: Whether TNFi dose tapering preserves low disease activity in PsA/axSpA patients already stable on a TNFi.Key limitations: effectiveness not the question · open-label · single centre · mixed indications
Primary RCT-derived evidence of adalimumab (TNFi) joint efficacy in PsA.
“At week 48, patients from the adalimumab arm of ADEPT (n = 151) had achieved American College of Rheumatology 20% improvement (ACR20), ACR50, and ACR70 response rates of 56%, 44%, and 30%, respectively.”
Panel auditInternal validity: medium · scope of inference: Long-term joint, skin, disability and radiographic outcomes of adalimumab in moderate-to-severe PsA.Key limitations: open-label extension for response rates · no concurrent placebo at week 48 for ACR · no p-values reported
Phase-3 RCT shows adalimumab (TNFi) ACR20 65.0% markedly exceeding placebo 36.2%.
Panel auditInternal validity: high · scope of inference: Efficacy of adalimumab (and upadacitinib) in non-biologic-DMARD-inadequate-responder PsA.Key limitations: p-value quoted is for UPA vs PBO, not explicitly ADA vs PBO · conference abstract
Real-world cohort showing adalimumab (TNFi) improves DAPSA in PsA.
“The DAPSA score improved in both groups, and between-treatment differences in DAPSA pathways over time were not significant.”
Panel auditInternal validity: medium · scope of inference: Real-world 12-month joint and skin outcomes of adalimumab relative to ixekizumab in a general PsA population.Key limitations: no placebo/untreated comparator · baseline channelling between arms · observational
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Converging randomised and large-registry evidence consistently and directionally supports TNFi efficacy in PsA, with residual uncertainty confined to effect magnitude rather than existence of effect.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Maintained placebo-controlled TNFi trial. The corpus lacks a sustained placebo comparison with a TNF inhibitor as the trial subject; existing adalimumab efficacy is open-label extension [7] or borrowed from a comparator arm [8]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised double-blind trial with a maintained placebo arm and a TNFi as the investigational drug, reporting ACR and structural endpoints.
Open question: Does a TNF inhibitor as the investigational subject beat placebo on ACR response in a sustained, blinded comparison within this evidence base? Why it is still open: The corpus offers only open-label extension data for adalimumab [7] and a placebo contrast from a trial where adalimumab is the comparator [8].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19